Hostname: page-component-74656f9884-6grmk Total loading time: 0 Render date: 2026-11-05T20:19:27.690Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacological treatment of mixed states

Published online by Cambridge University Press:  18 April 2017

Alessandro Cuomo ,
Viktoriya L. Nikolova ,
Nefize Yalin ,
Danilo Arnone ,
Andrea Fagiolini  and
Allan H. Young
Alessandro Cuomo
Affiliation:
General Psychiatry Residency Training Program, University of Siena School of Medicine, Siena, Italy
Viktoriya L. Nikolova
Affiliation:
Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College, London
Nefize Yalin
Affiliation:
Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College, London
Danilo Arnone
Affiliation:
Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College, London
Andrea Fagiolini
Affiliation:
Department of Medical Sciences, Surgery and Neurosciences, University of Siena School of Medicine, Siena, Italy
Allan H. Young*
Affiliation:
Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College, London
*
*Address for correspondence: Professor Allan H. Young, Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, PO72 De Crespigny Park, London SE5 8AF, United Kingdom. Email: (Allan.Young@kcl.ac.uk)
Rights & Permissions [Opens in a new window]

Abstract

Mixed states in bipolar disorder have been neglected, and the data concerning treatment of these conditions have been relatively obscure. To address this, we systematically reviewed published pharmacological treatment data for “mixed states/episodes” in mood disorders, including “with mixed features” in DSM–5. We searched PubMed, MEDLINE, The Cochrane Library, clinicaltrials.gov, and controlled-trials.com (with different combinations of the following keywords: “mixed states/features,” “bipolar,” “depressive symptoms/bipolar depression,” “manic symptoms,” “treatment,” “DSM–5”) through to October 2016. We applied a quality-of-evidence approach: first-degree evidence=randomized placebo-controlled studies of pharmacological interventions used as monotherapy; second-degree evidence=a similar design in the absence of a placebo or of a combination therapy as a comparative group; third-degree evidence=case reports, case series, and reviews of published studies. We found very few primary double-blind, placebo-controlled studies on the treatment of mixed states: the preponderance of available data derives from subgroup analysis performed on studies that originally involved manic patients. Future research should study the effects of treatments in mixed states defined using current criteria.

Keywords

Mixed states/episodesmood disordersDSM–5depressive symptomsmanic symptomstreatmentpharmacological interventionspharmacotherapies

Information

Type
Review Articles
Information
CNS Spectrums , Volume 22 , Issue 2: Theme: Mixed features in major depressive episodes , April 2017 , pp. 186 - 195
Copyright
© Cambridge University Press 2017 

Introduction

Mixed states present particular challenges to the treating clinician, and even the prevalence rate changes significantly among studies and in relation to the diagnostic criteria used. In the DSM–IV, a diagnosis of a mixed episode required simultaneously all criteria for a manic or a major depressive episode for a period of one week. Individuals infrequently meet these full criteria in clinical practice. The new DSM–5 “specifier” arguably adopts a broader approach toward mixed states. In the case of depressive episodes, there is a requirement for the presence of at least three manic/hypomanic symptoms (including elevated mood, inflated self-esteem, decreased need for sleep, an increase in energy or goal-directed activities, etc.) occurring nearly every day during a major depressive episode; notably, overlap with symptoms of major depression is restricted. In the case of mania or hypomania, the specifier requires the presence of at least three symptoms of depression (including depressed mood, diminished interest or pleasure, slowed physical and emotional reaction, fatigue or loss of energy, and recurrent thoughts of death, etc.) occurring nearly everyday throughout the manic or hypomanic episode.

Mixed states are generally held to be less responsive to pharmacological treatment, and the response to mood stabilizers and other pharmacotherapies is poor.Reference Swann, Lafer and Perugi 1 , Reference Vieta and Valenti 2 Antidepressants are generally avoided because of exacerbation of manic symptoms and a feared increased risk of suicidality, which is already high.Reference Castle 3 However, the use of an atypical antipsychotic/antimanic agent in some bipolar disorder patients may decrease suicidal ideation.Reference Houston, Ahl, Meyers, Kaiser, Tohen and Baldessarini 4 As a result, the choice of medication is usually based on individual factors and short-/long-term harms, safety, and tolerability parameters. The aim of this review is to summarize the pharmacological treatment of “mixed states/episodes” as defined by the DSM–III and the DSM–IV, and manic episodes “with mixed features” as defined in the DSM–5.

Methods

Searches

PubMed, MEDLINE, and The Cochrane Library were searched from January of 1980 to October of 2016 for all publications regarding treatment of mixed features as defined by the DSM–III and DSM–IV, and manic or depressive episodes “with mixed features” as defined in the DSM–5. The clinical trials registries in clinicaltrials.gov and controlled-trials.com were scrutinized for trials. The search was done using different combinations of the following keywords: “mixed states/features,” “bipolar disorder,” “depressive symptoms/bipolar depression,” “manic symptoms,” “treatment,” “DSM–5.” Related publications were hand-searched from the reference lists of every identified primary study.

Study selection

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)Reference Liberati, Altman and Tetzlaff 5 guidelines (see Figure 1). Articles were selected for inclusion in this review if they met the following criteria: (1) inclusion of a mixed-episode sample (or subgroup) was clearly stated; and (2) research findings for the mixed-episode sample (or subgroup) were presented. Nonoriginal studies (including editorials, book reviews, and letters to the editor) and studies without available full-text versions were excluded.

Figure 1

PRISMA flow diagram.

Quality assessment

First-degree studies included double-blind, placebo-controlled randomized controlled trials (RCTs) of pharmacological interventions used as monotherapy. Second-degree studies had a similar design without a placebo or combination therapy as a comparative group, while third-degree studies referred to any other type of published research.

Results

114 articles were assessed for eligibility, of which 54 investigated mixed states in bipolar disorder. However, while 36 of these studies included some number of patients experiencing a mixed episode at baseline, their focus was on pure mania, and the data from both groups were pooled and analyzed together. Several of these studies briefly reported some exploratory subgroup analysis or no significant effect of episode on treatment outcome when baseline episode (manic vs. mixed) was added as a covariate. These studies were excluded from the present review as the data reported are not sufficient to provide reliable estimates of treatment efficacy in patients with mixed states. Table 1 presents all the studies that were excluded at this final stage, organized by treatment. In addition, one article examining the effects of gabapentin as adjunctive treatment in mixed states was also excluded from this review as the full text of the publication could not be accessed.Reference Perugi, Toni, Ruffolo, Sartini, Simonini and Akiskal 42

Table 1

List of publications that included mixed patients in the total sample, but did not report results for the mixed-only subgroup

Following the exclusion of these articles, there were 18 studies that met the inclusion criteria and investigated mixed states in bipolar disorder as a separate group. Of these, only 7 studies specifically examined pharmacotherapy for mixed states and the remaining 11 included both manic and mixed episode patients but reported treatment effect separately for each subgroup. These studies evaluated antipsychotics, mood stabilizers, and combination therapies for acute (n=12), maintenance treatment (n=5), or both (n=1) in patients with DSM–III and DSM–IV mixed episodes or DSM–5 mixed features. Pharmacological evidence for each class of medication is presented in Table 2, and the sections below are organized according to aim of treatment (acute vs. maintenance) and drug. The primary findings, degree of evidence, and sample size are also presented in Table 2.

Table 2

Studies evaluating pharmacological treatments for mixed states in bipolar disorder during the acute or long-term/maintenance phase.

* > indicates ‘significantly superior’;=indicates ‘no significant difference’; ** 1- first-degree evidence: randomised placebo controlled studies of pharmacological interventions used in monotherapy; 2- second-degree evidence: absence of a placebo group or of combination therapy; 3- third degree evidence: case reports, case series or reviews of published studies; HAMD- Hamilton Depression Rating Scale, MADRAS- Montgomery-Asberg Depression Rating Scale, MRS- Mania Rating Scale, SADS-DSS- Schedule for Affective Disorders and Schizophrenia-Depressive Syndrome Scale, YMRS- Young Mania Rating Scale.

Acute Phase Studies

Antipsychotic medication

We identified six studies that evaluated the efficacy of antipsychotic medication in patients with mixed states.

Two first-degree studies compared aripiprazole with placebo and found that aripiprazole significantly decreased manic symptoms.Reference Suppes, Eudicone, McQuade, Pikalov and Carlson 43 , Reference Sachs, Sanchez and Marcus 44 Further, Sachs et al.Reference Sachs, Sanchez and Marcus 44 reported a significant reduction in depressive symptoms among patients taking aripiprazole compared to placebo. Suppes et al.Reference Suppes, Eudicone, McQuade, Pikalov and Carlson 43 also reported significantly higher response and remission rates (based on YMRS scores) among those treated with aripiprazole.

We identified two studies that examined the efficacy of ziprasidone.Reference Patkar, Gilmer and Pae 47 , Reference Stahl, Lombardo, Loebel and Mandel 48 One first-degree evidence trial comparing ziprasidone with placebo in major depressive episodes with 2 or 3 concomitant manic symptoms found ziprasidone to be superior to placebo in improving depressive, but not manic symptoms.Reference Patkar, Gilmer and Pae 47 One studyReference Stahl, Lombardo, Loebel and Mandel 48 is also available from a pooled analysis of mixed patients with dysphoric mania previously enrolled in two similar placebo-controlled trials.Reference Keck, Versiani, Potkin, West, Giller and Ice 30 , Reference Potkin, Keck, Segal, Ice and English 31 This study found ziprasidone to be significantly superior to placebo in improving both manic and depressive symptoms. Response and remission rates were also significantly higher in the ziprasidone group.

In a first-degree placebo-controlled trial, McIntyre et al.Reference McIntyre, Cohen, Zhao, Alphs, Macek and Panagides 45 found that the effect of treatment with sublingual asenapine (compared to placebo) on manic symptoms only approached significance, while the effect was significantly greater in the group treated with olanzapine (compared to placebo).

In a recent first-degree trial, Suppes et al.Reference Suppes, Silva and Cucchiaro 46 evaluated the efficacy of lurasidone in major depression with mixed features and found that lurasidone significantly improved both depressive and manic symptoms, and a significantly higher proportion of patients in the lurasidone group met a-priori response and remission criteria (number needed to treat [NNT] of 3 and 4, respectively).

Finally, in a case series by Suppes et al.Reference Suppes, McElroy, Gilbert, Dessain and Cole 49 (not included in the table), patients were treated with clozapine in both the acute and maintenance phases. Seven subjects had treatment-resistant bipolar disorder and manic episodes associated with significant depressive symptoms. All patients displayed significant reductions in affective and psychotic symptoms when treated with clozapine alone or in combination with lithium, an antidepressant, or valproate.

Mood stabilizers

We found only one study that satisfied our inclusion criteria. This was a post-hoc analysis by Weisler et al.Reference Weisler, Hirschfeld and Cutler 50 of data from two studiesReference Weisler, Kalali and Ketter 51 , Reference Weisler, Keck, Swann, Cutler, Ketter and Kalali 52 that evaluated the efficacy of carbamazepine (extended-release capsules) versus placebo in patients with manic or mixed episodes. Carbamazepine significantly improved both manic and depressive symptoms in the subsample of mixed patients.

Combination therapy

We identified five first-degree trials that met our inclusion criteria. Three trials compared the efficacy of olanzapine in combination with a mood stabilizer (lithium or valproate) versus placebo and presented data for the mixed-patients group.Reference Houston, Tohen, Degenhardt, Jamal, Liu and Ketter 53 – Reference Baker, Brown and Akiskal 55 Overall, the results from all three studies indicated that adjunctive olanzapine treatment is superior to mood stabilizer monotherapy in improving both depressive and manic symptoms. Conversely, one trial examining the efficacy of a olanzapine/fluoxetine combination for the treatment of mixed depression reported no statistically significant difference in depressive symptoms between patients who received both olanzapine and fluoxetine and those who received olanzapine alone.Reference Benazzi, Berk, Frye, Wang, Barraco and Tohen 56

Finally, Suppes et al.Reference Suppes, Ketter and Gwizdowski 57 assessed adjunctive quetiapine treatment (to any stable cooccurring treatment) in hypomanic patients experiencing mixed symptoms. Quetiapine adjunctive treatment was significantly more effective in improving depressive, but not hypomanic symptoms.

Long-Term (≥8 Weeks), Maintenance and Relapse Prevention Studies

Antipsychotic medication

We found one post-hoc analysis of a randomized placebo-controlled trial that compared olanzapine with placebo in mixed-episode patients for 6 to 12 weeks. The results indicated that olanzapine-treated patients had significantly lower rates of symptomatic relapse of any kind compared with placebo, with a reported NNT of 4 to prevent one episode of symptomatic relapse.Reference Tohen, Calabrese and Sachs 58 , Reference Tohen, Sutton, Calabrese, Sachs and Bowden 59

Mood stabilizers

Two first-degree trials met our inclusion criteria: one of valproate and one of carbamazepine. Bowden et al.Reference Bowden, Collins and McElroy 60 provided randomized maintenance treatment with valproate, lithium, or placebo to euphoric and dysphoric patients. Among the dysphoric patients, there were no statistically significant treatment-related differences on time to relapse nor on manic and depressive scores.

Ketter et al.Reference Ketter, Kalali and Weisler 61 examined the efficacy of carbamazepine extended-release capsules as maintenance therapy in bipolar patients with manic and mixed episodes in an open-label extension study of two double-blind placebo-controlled trials. Separate data analysis of the mixed subgroup was only reported for depressive symptoms, where carbamazepine treatment maintained the significant decrease of depressive symptoms observed at the end of the double-blind studies.

Combination therapy

One first-degree study of aripiprazole+lamotrigine combination therapy was found.Reference Carlson, Ketter and Sun 62 Time to relapse in the mixed-state group was significantly longer in the aripiprazole+lamotrigine group compared to the placebo+lamotrigine group in this study.

Finally, in a 24-week open-label (second-degree) combination trial, Woo et al.Reference Woo, Bahk and Jon 63 investigated the efficacy of risperidone in combination with mood stabilizers. A significant improvement from mean baseline was reported for both manic and depressive symptoms among mixed-episode patients.

Discussion

We found that the vast majority of published RCTs initially recruited both pure manic and mixed patients as defined by the DSM–IV classification system and that additional analyses were performed to identify effects in the subgroup of mixed patients only in a small proportion of these studies. This subgroup approach has several shortcomings. First, the resulting sample sizes are usually small, and thus “negative” trials could have been underpowered to detect existing differences between treatment groups. Second, the enrollment criteria in many of these studies were based on manic symptom severity alone, and there was no minimum depressive score cut-off, suggesting that the mixed patients enrolled could be less severely ill than those seen in clinical practice or that they may not be representative of the full spectrum. Third, the categorical definition in the DSM–IV limits the number of patients identified, since it requires the co-occurrence of a full manic and a full depressive episode. The new DSM–5 specifier, however, has the potential to address this latter issue, as it is likely that it will increase the detection and reporting of mixed states from both ends of the spectrum. A further major shortfall of the literature is that mixed depressive cases are not usually reported in depression RCTs. Additionally, there were only seven studies identified in the literature that exclusively examined pharmacotherapy for the mixed manic or depressive state. Due to the low number of studies, the variety of pharmacological interventions tested, the differences in methodology and in the aim of treatment (acute vs. maintenance), it is not possible to draw informative conclusions for clinical practice at the present point in time.

Some limitations of our work must be acknowledged. Although our search strategy was comprehensive, there is still the chance that relevant papers or studies have been missed. This review did not include books or clinical trials that looked at the effects of other nonpharmacological treatment modalities, such as psychosocial interventions or electroconvulsive therapy. We reported results distinguishing between manic and depressive outcomes when available, which may be more in line with the clinical need to understand to what extent the chosen medication is able to resolve both manic and depressive symptoms in mixed states or, conversely, to independently treat one or the other. Moreover, this is in line with the new “mixed-features” categorization of mood episodes in the DSM–5, as the distinction in efficacy based on the polarity of concomitant symptoms may be more applicable to the clinical setting.

In summary, the currently available evidence does not meet clinicians’ demands. Therefore, there is a clear need to conduct well-powered clinical trials specifically designed to enroll the full range of mixed features using current criteria.

Disclosures

Alessandro Cuomo, Viktoriya Nikolova, Nefize Yalin, and Danilo Arnone hereby declare that they do not have anything to disclose.

Andrea Fagiolini reports grants and personal fees from Allergan, Angelini, Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Eli Lilly, Janssen, Lundbeck, Novartis, Otsuka, and Roche, outside the submitted work.

Allan Young has the following disclosures. Employed by King’s College London. Honorary consultant SLaM (NHS UK). Paid lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders. No shareholdings in pharmaceutical companies. Lead Investigator for the Embolden Study (AZ), the BCI Neuroplasticity Study, and the Aripiprazole Mania Study. Investigator-initiated studies from AZ, Eli Lilly, Lundbeck, and Wyeth. Grant funding (past and present): NIMH (USA), CIHR (Canada), NARSAD (USA), Stanley Medical Research Institute (USA), MRC (UK), Wellcome Trust (UK). the Royal College of Physicians (Edin), BMA (UK), UBC–VGH Foundation (Canada), WEDC (Canada), CCS Depression Research Fund (Canada), MSFHR (Canada), and NIHR (UK).

Footnotes

We thank Ms. Caroline Loveland for her help in preparing this manuscript. Dr. Danilo Arnone is supported by the Academy of Medical Sciences (AMS-SGCL8).

This paper represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London, the Maudsley NHS Foundation Trust, and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

References

1. Swann, AC, Lafer, B, Perugi, G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013; 170(1): 31–42. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2012.12030301. Accessed January 8, 2017.CrossRefGoogle ScholarPubMed
2. Vieta, E, Valenti, M. Mixed states in DSM–5: implications for clinical care, education, and research. J Affect Disord. 2013; 148(1): 28–36. Epub ahead of print Apr 2. http://www.jad-journal.com/article/S0165-0327(13)00232-2/pdf. Accessed January 8, 2017.Google Scholar
3. Castle, DJ. Bipolar mixed states: still mixed up? Curr Opin Psychiatry. 2014; 27(1): 38–42.Google Scholar
4. Houston, JP, Ahl, J, Meyers, AL, Kaiser, CJ, Tohen, M, Baldessarini, RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry. 2006; 67(8): 1246–1252.Google Scholar
5. Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4): W65–W94. Epub ahead of print Jul 20.Google Scholar
6. Tohen, M, Sanger, TM, McElroy, SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999; 156(5): 702–709. http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.156.5.702. Accessed January 8, 2017.Google Scholar
7. Tohen, M, Jacobs, TG, Grundy, SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000; 57(9): 841–849. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/205739. Accessed January 8, 2017.Google Scholar
8. Novick, D, Reed, C, Haro, JM, et al. Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010; 25(5): 257–263.Google Scholar
9. Perlis, RH, Baker, RW, Zarate, CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry. 2006; 67(11): 1747–1753.Google Scholar
10. Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, et al. A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003; 60(12): 1218–1226. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/208076. Accessed January 8, 2017.CrossRefGoogle ScholarPubMed
11. Tohen, M, Greil, W, Calabrese, JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005; 162(7): 1281–1290. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.162.7.1281. Accessed January 8, 2017.CrossRefGoogle ScholarPubMed
12. McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009; 11(8): 815–826. Epub ahead of print Oct 14.CrossRefGoogle Scholar
13. Tohen, M, Ketter, TA, Zarate, CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003; 160(7): 1263–1271. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.7.1263. Accessed January 8, 2017.Google Scholar
14. Tohen, M, Chengappa, KN, Suppes, T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004; 184: 337–345. http://bjp.rcpsych.org/content/184/4/337.long. Accessed January 8, 2017.Google Scholar
15. Weisler, RH, Nolen, WA, Neijber, A, Hellqvist, A, Paulsson, B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry. 2011; 72(11): 1452–1464.Google Scholar
16. Vieta, E, Suppes, T, Eggens, I, Persson, I, Paulsson, B, Brecher, M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008; 109(3): 251–263. Epub ahead of print Jun 24.Google Scholar
17. Suppes, T, Vieta, E, Liu, S, Brecher, M, Paulsson, B. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009; 166(4): 476–488. Epub ahead of print Mar 16. http://ajp.psychiatryonline.org/doi/pdfplus/10.1176/appi.ajp.2008.08020189. Accessed January 8, 2017.Google Scholar
18. Keck, PE Jr, Marcus, R, Tourkodimitris, S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003; 160(9): 1651–1658. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.9.1651. Accessed January 8, 2017.CrossRefGoogle ScholarPubMed
19. Keck, PE, Orsulak, PJ, Cutler, AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009; 112(1–3): 36–49. Epub ahead of print Oct 2, 2008.CrossRefGoogle Scholar
20. Young, AH, Oren, DA, Lowy, A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2008, 194(1): 40–48. http://bjp.rcpsych.org/content/194/1/40.long. Accessed January 8, 2017.Google Scholar
21. Keck, PE Jr, Calabrese, JR, McIntyre, RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007; 68(10): 1480–1491.Google Scholar
22. Findling, RL, Nyilas, M, Forbes, RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009; 70(10): 1441–1451.Google Scholar
23. Vieta, E, Bourin, M, Sanchez, R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005; 187: 235–242. http://bjp.rcpsych.org/content/187/3/235.long. Accessed January 8, 2017.Google Scholar
24. Vieta, E, T’Joen, C, McQuade, RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008; 165(10): 1316–1325. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2008.07101560. Accessed January 8, 2017.Google Scholar
25. Marcus, R, Khan, A, Rollin, L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 2011; 13(2): 133–144.Google Scholar
26. Vieta, E, Owen, R, Baudelet, C, McQuade, RD, Sanchez, R, Marcus, RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin. 2010; 26(6): 1485–1496.CrossRefGoogle Scholar
27. McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010; 126(3): 358–365.Google Scholar
28. McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010; 122(1–2): 27–38.Google Scholar
29. Bowden, CL, Vieta, E, Ice, KS, Schwartz, JH, Wang, PP, Versavel, M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010; 71(2): 130–137.Google Scholar
30. Keck, PE Jr, Versiani, M, Potkin, S, West, SA, Giller, E, Ice, K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003; 160(4): 741–748. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.4.741. Accessed January 8, 2017.Google Scholar
31. Potkin, SG, Keck, PE Jr, Segal, S, Ice, K, English, P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005; 25(4): 301–310.Google Scholar
32. Vieta, E, Nuamah, IF, Lim, P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010; 12(3): 230–243.Google Scholar
33. Berwaerts, J, Xu, H, Nuamah, I, Lim, P, Hough, D. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose–response study. J Affect Disord. 2012; 136(1–2): e51–e60. Epub ahead of print Jul 10, 2010.Google Scholar
34. Khanna, S, Vieta, E, Lyons, B, Grossman, F, Eerdekens, M, Kramer, M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005; 187: 229–234. http://bjp.rcpsych.org/content/187/3/229.long. Accessed January 8, 2017.CrossRefGoogle ScholarPubMed
35. Sachs, GS, Greenberg, WM, Starace, A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disorders. 2015; 174: 296–302. Epub ahead of print Nov 24, 2014. http://www.jad-journal.com/article/S0165-0327(14)00728-9/pdf. Accessed January 8, 2017.Google Scholar
36. Durgam, S, Starace, A, Li, D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015; 17(1): 63–75. Epub ahead of print Jul 24, 2014.Google Scholar
37. Calabrese, JR, Keck, PE Jr, Starace, A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015; 76(3): 284–292.Google Scholar
38. Bowden, CL, Swann, AC, Calabrese, JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006; 67(10): 1501–1510.Google Scholar
39. Freeman, TW, Clothier, JL, Pazzaglia, P, Lesem, MD, Swann, AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992; 149(1): 108–111.Google Scholar
40. Bowden, CL, Calabrese, JR, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60(4): 392–400. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/207328. Accessed January 8, 2017.Google Scholar
41. Calabrese, JR, Bowden, CL, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003; 64(9): 1013–1024.Google Scholar
42. Perugi, G, Toni, C, Ruffolo, G, Sartini, S, Simonini, E, Akiskal, H. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiatry. 1999; 32(4): 136–141.Google Scholar
43. Suppes, T, Eudicone, J, McQuade, R, Pikalov, A 3rd, Carlson, B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord. 2008; 107(1–3): 145–154. Epub ahead of print Sep 27, 2007.Google Scholar
44. Sachs, G, Sanchez, R, Marcus, R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006; 20(4): 536–546. http://journals.sagepub.com/doi/pdf/10.1177/0269881106059693. Accessed January 8, 2017.Google Scholar
45. McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009; 11(7): 673–686.Google Scholar
46. Suppes, T, Silva, R, Cucchiaro, J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173(4): 400–407. Epub ahead of print Nov 10, 2015.Google Scholar
47. Patkar, A, Gilmer, W, Pae, CU, et al. A 6-week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PloS One. 2012; 7(4): e34757. Epub ahead of print Apr 24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335844/. Accessed January 8, 2017.Google Scholar
48. Stahl, S, Lombardo, I, Loebel, A, Mandel, FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord. 2010; 122(1–2): 39–45. Epub ahead of print Jul 17, 2009.Google Scholar
49. Suppes, T, McElroy, SL, Gilbert, J, Dessain, EC, Cole, JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry. 1992; 32(3): 270–280.Google Scholar
50. Weisler, RH, Hirschfeld, R, Cutler, AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs. 2006; 20(3): 219–231.Google Scholar
51. Weisler, RH, Kalali, AH, Ketter, TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004; 65(4): 478–484.Google Scholar
52. Weisler, RH, Keck, PE Jr, Swann, AC, Cutler, AJ, Ketter, TA, Kalali, AH. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005; 66(3): 323–330.Google Scholar
53. Houston, JP, Tohen, M, Degenhardt, EK, Jamal, HH, Liu, LL, Ketter, TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry. 2009; 70(11): 1540–1547. Epub ahead of print Sep 22.CrossRefGoogle ScholarPubMed
54. Tohen, M, Chengappa, KN, Suppes, T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002; 59(1): 62–69.Google Scholar
55. Baker, RW, Brown, E, Akiskal, HS, et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry. 2004; 185: 472–478. http://bjp.rcpsych.org/content/185/6/472.long. Accessed January 8, 2017.Google Scholar
56. Benazzi, F, Berk, M, Frye, MA, Wang, W, Barraco, A, Tohen, M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry. 2009; 70(10): 1424–1431.Google Scholar
57. Suppes, T, Ketter, TA, Gwizdowski, IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord. 2013; 150(1): 37–43. Epub ahead of print Mar 19.Google Scholar
58. Tohen, M, Calabrese, JR, Sachs, GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006; 163(2): 247–256. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.163.2.247. Accessed January 8, 2017.CrossRefGoogle ScholarPubMed
59. Tohen, M, Sutton, VK, Calabrese, JR, Sachs, GS, Bowden, CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord. 2009; 116(1–2): 43–50. Epub ahead of print Dec 2, 2008.Google Scholar
60. Bowden, CL, Collins, MA, McElroy, SL, et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology. 2005; 30(10): 1932–1939. http://www.nature.com/npp/journal/v30/n10/pdf/1300788a.pdf. Accessed January 8, 2017.Google Scholar
61. Ketter, TA, Kalali, AH, Weisler, RH. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004; 65(5): 668–673.Google Scholar
62. Carlson, BX, Ketter, TA, Sun, W, et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord. 2012; 14(1): 41–53.Google Scholar
63. Woo, YS, Bahk, WM, Jon, DI, et al. Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea. Psychiatry Clin Neurosci. 2010; 64(1): 28–37. Epub ahead of print Nov 4, 2009.Google Scholar
Figure 0

Figure 1 PRISMA flow diagram.

Figure 1

Table 1 List of publications that included mixed patients in the total sample, but did not report results for the mixed-only subgroup

Figure 2

Table 2 Studies evaluating pharmacological treatments for mixed states in bipolar disorder during the acute or long-term/maintenance phase.